首页 | 本学科首页   官方微博 | 高级检索  
   检索      

人4-1BBL胞外区/抗CD20 Fab’融合蛋白的构建和表达
引用本文:姜文国,熊冬生,刘芳,郭红星,苏晔,吕晶丽,杨纯正.人4-1BBL胞外区/抗CD20 Fab’融合蛋白的构建和表达[J].生物工程学报,2008,24(3):376-380.
作者姓名:姜文国  熊冬生  刘芳  郭红星  苏晔  吕晶丽  杨纯正
作者单位:1. 滨州医学院,滨州,256603
2. 中国协和医学科大学/中国医学科学院血液学研究所实验血液学国家重点实验室,天津,300020
基金项目:国家高技术研究发展计划(863)资助 (No. 2003AA215080); 山东省自然科学基金资助(No. Q2006C02)。
摘    要:研究共刺激分子4-1BBL在肿瘤靶向治疗方面的作用, 用PCR 和overlap PCR 方法构建人4-1BBL胞外区/抗CD20 Fab’融合蛋白表达载体, 并用双脱氧终止法测定DNA 序列; 采用亲和层析法纯化该产物, 并用SDS-PAGE和HPLC鉴定纯化产物; 采用玫瑰花环试验鉴定纯化产物与靶细胞的结合活性。DNA 序列测定结果表明: 人4-1BBL胞外区/抗CD20 Fab’融合蛋白已构建成功。表达可溶性产物的产量达200 mg/L以上, 纯度较高, 具有与激活的Jurkat (4-1BBL+) 和Raji细胞(CD20+)结合的活性。这将为非何杰金氏淋巴瘤免疫治疗、靶向治疗提供新的思路。

关 键 词:4-1BBL    CD20    靶向治疗    免疫治疗
收稿时间:2007-06-19
修稿时间:2007-08-30

Study on the Construction and Expression of the Human 4-1BBL Extracellular Domain/anti-CD20 Fab' Fusion Protein
Wenguo Jiang,Dongsheng Xiong,Fang Liu,Hongxing Guo,Ye Su,Jingli Lü,Chunzheng Yang.Study on the Construction and Expression of the Human 4-1BBL Extracellular Domain/anti-CD20 Fab' Fusion Protein[J].Chinese Journal of Biotechnology,2008,24(3):376-380.
Authors:Wenguo Jiang  Dongsheng Xiong  Fang Liu  Hongxing Guo  Ye Su  Jingli Lü  Chunzheng Yang
Institution:Binzhou Medical College, Binzhou 256603, China;The State Key Laboratory of Experimental Hematology, Institute of Hematology, CAMS & PUMC, Tianjin 300020, China;The State Key Laboratory of Experimental Hematology, Institute of Hematology, CAMS & PUMC, Tianjin 300020, China;The State Key Laboratory of Experimental Hematology, Institute of Hematology, CAMS & PUMC, Tianjin 300020, China;The State Key Laboratory of Experimental Hematology, Institute of Hematology, CAMS & PUMC, Tianjin 300020, China;The State Key Laboratory of Experimental Hematology, Institute of Hematology, CAMS & PUMC, Tianjin 300020, China;The State Key Laboratory of Experimental Hematology, Institute of Hematology, CAMS & PUMC, Tianjin 300020, China
Abstract:Several studies have demonstrated the role of 4-1BBL in T cell activation. Furthermore, enhanced 4-1BB/4-1BBL interaction has been shown to amplify T-cell-mediated antitumor immunity in several mouse models. However, when applied in humans, it was difficult to generate sufficient T cells ex vivo and whole cell vaccines to transfer back into patients. To overcome this difficulty, we have focused on producing the human 4-1BBL extracellular domain/anti-CD20 Fab' fusion protein. In this report, PCR and overlap PCR were used to construct the human 4-1BBL extracellular domain/anti-CD20 Fab' expression vector. DNA sequence was analyzed by the Terminus of Dideoxy Nucleotide. The product was purified by affinity chromatography and analyzed by SDS-PAGE and HPLC; its antigen binding activity was examined by rosetting assay. The data of DNA sequence showed that the human 4-1BBL extracellular domain/anti-CD20 Fab' fusion protein was corrected. The fusion protein was recovered in high yield (up to 200 microg/mL) after E-taq purification. The fusion protein was capable of simultaneous binding to stimulated Jurkat cells and Raji cells as shown by cellular rosetting. In conclusion, the human 4-1BBL extracellular domain/anti-CD20 Fab' fusion protein was induced to express in E. coli 16C9. The results of some biological activity experiments indicated that the fusion protein could bind to stimulated Jurkat cells and Raji cells. Furthermore, 4-1BBL-negative tumors can be converted into 4-1BBL-positive tumors by the fusion protein without the need for 4-1BBL gene transfer to the malignant cells.
Keywords:4-1BB ligand  CD20  targeting therapy  cancer immunotherapy
本文献已被 维普 万方数据 等数据库收录!
点击此处可从《生物工程学报》浏览原始摘要信息
点击此处可从《生物工程学报》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号